

Cover image: Part of 'The Dresden Altar' by Albrecht Dürer (1471–1528), Alte Meister Gallerie, Dresden, Germany.

#### Editor

Tore K Kvien

#### Associate Editors

Francis Berenbaum

Hans Bijlsma

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

#### Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: [ard@bmj.com](mailto:ard@bmj.com)

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 7.188

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2010 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Mercury International Ltd, 365 Blair Road, Avenel, NJ 07001, USA.

## Advances in targeted therapies XI

### Preface

- i1** Advances in targeted therapies XI  
*F C Breedveld, J R Kalden, J S Smolen*


### Consensus statement

- i2** Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009  
*D E Furst, E C Keystone, R Fleischmann, P Mease, F C Breedveld, J S Smolen, J R Kalden, J Braun, B Bresnihan, G R Burmester, F De Benedetti, T Dörner, P Emery, A Gibofsky, A Kavanaugh, B Kirkham, M H Schiff, J Sieper, N Singer, P L C M Van Riel, M E Weinblatt, M H Weisman, K Winthrop*

### Papers

- i30** Evidence for microRNA-mediated regulation in rheumatic diseases  
*X Luo, L M Tsai, N Shen, D Yu*
- i37** Does gene expression analysis inform us in rheumatoid arthritis?  
*T Häupl, B Stuhlmüller, A Grützke, A Radbruch, G-R Burmester*
- i43** Role of interleukin 33 in human immunopathology  
*G E J Murphy, D Xu, F Y Liew, I B McInnes*
- i48** Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies  
*J H W Distler, O Distler*
- i52** What are the new milestones in the pathogenesis of systemic sclerosis?  
*N Hunzelmann, J Brinckmann*
- i57** Inflammation, vascular injury and repair in rheumatoid arthritis  
*A J van Zonneveld, H C de Boer, E P van der Veer, T J Rabelink*
- i61** Heart disease and rheumatoid arthritis: understanding the risks  
*S E Gabriel*
- i65** Treg and lupus  
*M Bonelli, J S Smolen, C Scheinecker*
- i67** XBP1: the last two decades  
*L H Glimcher*
- i72** Can we prevent immunogenicity of human protein drugs?  
*D W Scott, A S De Groot*
- i77** "Go upstream, young man": lessons learned from the p38 saga  
*D Hammaker, G S Firestein*
- i83** The role of cell–substrate interaction in regulating osteoclast activation: potential implications in targeting bone loss in rheumatoid arthritis  
*K P McHugh, Z Shen, T N Crotti, M R Flannery, R P O'Sullivan, P E Purdue, S R Goldring*
- i86** Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)  
*E F Wagner*
- i89** The value of productivity: human-capital versus friction-cost method  
*W B van den Hout*
- i92** The pro and anti-inflammatory activities of immunoglobulin G  
*A Lux, S Aschermann, M Biburger, F Nimmerjahn*
- i97** What have we learnt from targeted anti-TNF therapy?  
*M Feldmann, R O Williams, E Paleolog*

## Take the pain out of research every month



Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 7.188, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for just £250 a year (€338, \$487). Too much paper on your desk already? An online subscription is just £111 (€150, \$217).

Visit [group.bmj.com/group/subs-sales](http://group.bmj.com/group/subs-sales) - your subscription to this first class journal is just a few clicks away.

[ard.bmj.com](http://ard.bmj.com) BMJ Journals